ACDIS Updated CCDS-O Exam Questions and Answers by kylian

In obstetric and postpartum coding, the most important clarification is thetype/timingof hypertension because ICD-10-CM has distinct categories for chronic (pre-existing) hypertension, gestational hypertension, and hypertensive disorders that persist into or present during the postpartum period. At 6 weeks postpartum with elevated readings (including a systolic of 160) and headache, the documentation “hypertension” is not specific enough to determine whether this represents chronic hypertension that predates pregnancy, gestational hypertension that has not resolved, or another pregnancy-related hypertensive disorder requiring different obstetric coding and follow-up. ACDIS outpatient CDI guidance prioritizes queries that resolve coding-impactful ambiguity using clinically supported options without leading the provider. While postpartum preeclampsia could be a clinical consideration, the note does not provide key supporting elements (e.g., proteinuria or other definitive severe-feature criteria), so jumping directly to preeclampsia/eclampsia is less appropriate than clarifying onset and relationship to pregnancy. Linking hypertension to smoking is not a standard required linkage for diagnosis coding, and “hypertensive crisis” is not supported by the documentation provided.

The definition in option B is the official Uniform Hospital Discharge Data Set (UHDDS) definition used for inpatient coding: the principal diagnosis is the condition determined—after evaluation—to be chiefly responsible for the admission. It is not simply the first condition written, nor necessarily the “worst” or most severe condition; it is the reason for admission once the workup clarifies the clinical picture. CDI practice reinforces this because principal diagnosis selection drives DRG assignment, quality metrics, and reporting, and errors often stem from confusing presenting symptoms with the final established diagnosis. Although outpatient settings use different concepts (e.g., first-listed diagnosis for the encounter), ACDIS education frequently contrasts inpatient “principal diagnosis” with outpatient “first-listed” to prevent documentation and coding misalignment. Clinicians should document the definitive condition when known (and link symptoms to that condition), and clearly describe diagnostic uncertainty when not yet established. This clarity supports compliant coding, accurate benchmarking, and defensible medical necessity across settings.

Stage 3 pressure ulcers are defined byfull-thickness skin losswhere the injury extends through the dermis and involvesdamage or necrosis of subcutaneous tissue. Clinically, the ulcer may present as a deep crater and can include undermining or tunneling, but the key boundary is thatbone, tendon, and muscle are not exposed. That deeper involvement (exposed muscle/tendon/bone) is characteristic of Stage 4, making option C incorrect. Option D describes partial-thickness loss, which aligns with Stage 2 (epidermis/dermis involvement such as abrasion or blister). Option A reflects early skin changes that correspond more closely to Stage 1 (intact skin with non-blanchable erythema and possible localized edema/induration). In outpatient CDI chart review, accurately distinguishing Stage 3 from Stage 2 and Stage 4 is essential because staging drives severity capture, care planning (wound care interventions, debridement considerations), and quality reporting. Documentation should clearly support “full thickness,” the tissue layers involved, and the absence of exposed bone/tendon/muscle.

Symbicort is an inhaled combination medication containing an inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA). In outpatient chart review, this medication class is most strongly associated with chronic airway inflammatory diseases requiring controller therapy—especiallypersistent asthma(and also maintenance therapy for COPD, though COPD is not an option here). For CDI purposes, medication-to-diagnosis linkage can act as a clinical indicator supporting clarification when the visit note lists respiratory symptoms but does not clearly document the chronic condition being treated or its acuity/status. Symbicort is not used to treat musculoskeletal degenerative disease (osteoarthritis), peripheral nerve pain from diabetes (diabetic neuropathy), or cardiac pump failure (congestive heart failure). When Symbicort appears on the active med list, outpatient CDI commonly checks that the provider’s documentation appropriately reflects asthma classification (intermittent vs persistent), current control, exacerbation status if applicable, and that the condition is being monitored/assessed/treated during the encounter to support reportability and accurate coding.